The concern of generic rivalry has consistently loomed over copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the prospects of similar drug investments. While first times saw substantial returns, the patent expiration has created the door for less expensive alternatives, potentially reducing earnings and creating a genuine risk